{"url_path":"/sec/aqst/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1398733/0001398733-26-000030-index.html","accession_number":"0001398733-26-000030","cik":"0001398733","ticker":"AQST","issuer_name":"Aquestive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1398733/0001398733-26-000030-index.html","primary_entity_key":"0001398733","primary_entity_name":"Aquestive Therapeutics, Inc."},"word_count":484,"has_tables":true,"body_markdown":"Item 6.    Exhibits\n\nThe exhibits listed below are filed or furnished as part of this report.\n\nNumberDescription\n\n[4.1](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/formofaquestive2026warra.htm)\nForm of Warrant (filed as Exhibit 4.1 to the Current Report on Form 8-K of the Company, as filed on March 4, 2026, and incorporated by reference herein).\n\n[10.1](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/amdno1rtw-aqstxfeb2026ex.htm)\nAmendment No. 1 to the Purchase and Sale Agreement, dated August 13, 2025, by and between the Company and funds managed by RTW Investments, LP, dated March 3, 2026 (filed as Exhibit 10.1 to the Current Report on Form 8-K of the Company, as filed on March 4, 2026, and incorporated by reference herein).\n\n[10.2](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/warrantissuanceagreement.htm)\nWarrant Issuance Agreement, by and between the Company and funds managed by RTW Investments, LP, dated March 3, 2026 (filed as Exhibit 10.2 to the Current Report on Form 8-K of the Company, as filed on March 4, 2026, and incorporated by reference herein).\n\n[10.3](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/equitycommitmentagreemen.htm)\nShare Purchase Commitment Agreement, by and between the Company and the parties thereto, dated March 3, 2026 (filed as Exhibit 10.3 to the Current Report on Form 8-K of the Company, as filed on March 4, 2026, and incorporated by reference herein).\n\n[10.4](ljb_terminationxemployme.htm)*\nTermination of Executive Employment Agreement dated as of March 16, 2026, by and between Aquestive Therapeutics, Inc. and Lori J. Braender.\n\n[10.5](ljb_employmentxageementx.htm)*\nExecutive Employment Agreement dated as of March 16, 2026, by and between Aquestive Therapeutics, Inc. and Lori J. Braender.\n\n[31.1](q12026ex311.htm)*\nCertification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a), as amended, under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).\n\n[31.2](q12026ex312.htm)*\nCertification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a), as amended, under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).\n\n[32.1](q12026ex321.htm)*\nCertification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).\n\n[32.2](q12026ex322.htm)*\nCertification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).\n\n101.INS*XBRL Instance Document\n\n101.SCH*XBRL Taxonomy Extension Schema Document\n\n101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF*XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB*XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document\n\n104*Cover Page Interactive Data File (formatted as Inline XBRL document and contained in exhibit 101)\n\n* Filed herewith.\n\n48\n\n[Table of](#i65b3f6374bb0418bacd030f2ff357555_7)[Contents](#i65b3f6374bb0418bacd030f2ff357555_7)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Somerset, State of New Jersey.\n\nAquestive Therapeutics, Inc.\n(REGISTRANT)\n\n \n\nDate:May 13, 2026/s/ Daniel Barber\n\n Daniel Barber\n\n President and Chief Executive Officer\n\n (Principal Executive Officer)\n\n  \n\nDate:May 13, 2026/s/ A. Ernest Toth, Jr.\n\n A. Ernest Toth, Jr.\n\n Chief Financial Officer\n\n (Principal Financial Officer)\n\n49"}